Earnings Call Transcript January 30, 2025 Sanofi misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were ...

Sanofi (NASDAQ:SNY – Get Free Report) was upgraded by stock analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a report released on Thursday, Marketbeat Ratings ...

Deutsche Bank (ETR:DBKGn) analyst Emmanuel Papadakis upgraded Sanofi (NASDAQ:SNY) stock from Sell to Hold and increased the ...

Bernstein SocGen Group revised its price target for Regeneron (NASDAQ:REGN) Pharmaceuticals (NASDAQ: REGN) to $1,000 from the previous $1,070, while retaining an Outperform rating on the stock.

Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...

Sanofi (SNYNF – Research Report) received a Buy rating and price target from DZ BANK AG analyst Elmar Kraus today. The company’s shares ...

In a report released on January 30, David Evans from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report), with a price ...

DZ Bank upgraded Sanofi (SNY) to Buy from Hold with a EUR 122 price target Invest with Confidence: Follow TipRanks' Top Wall Street Analysts to ...

In a report released today, Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNY – Research Report). The ...

Tractor Supply (NASDAQ:TSCO – Get Free Report)‘s stock had its “outperform” rating restated by Telsey Advisory Group in a report released on Thursday,Benzinga reports. They presently have a $67.00 ...

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4: sales growth of 10.3% at CER 1and business EPS 2of €1.

Clinical-stage USA-based drug developer Inhibikase Therapeutics saw its shares tumble more than 31% to $1.92, after is ...